Tocilizumab in hospitalized patients with COVID-19: Clinical outcomes, inflammatory marker kinetics, safety, and a review of the literature
| Autor: | Mark M. Wurfel, Cameron J. Turtle, Jing Huang, Margaret L. Green, Danika Bethune, Christine Johnston, Kim Hn, Manoj Menon, Guang-Shing Cheng, Wendy M. Leisenring, Joshua A. Hill, Shireesha Dhanireddy, Hu Xie, Jeannie D. Chan, Rupali Jain |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2020 |
| Předmět: |
musculoskeletal diseases
medicine.medical_specialty business.industry Proportional hazards model Inverse probability weighting Hazard ratio Retrospective cohort study Fibrinogen chemistry.chemical_compound Tocilizumab chemistry Internal medicine Propensity score matching Transaminitis Medicine business skin and connective tissue diseases medicine.drug |
| DOI: | 10.1101/2020.08.05.20169060 |
| Popis: | BackgroundCoronavirus disease 2019 (COVID-19) due to infection with SARS-CoV-2 causes substantial morbidity. Tocilizumab, an interleukin-6 receptor antagonist, might improve outcomes by mitigating inflammation.MethodsWe conducted a retrospective study of patients admitted to the University of Washington Hospital system with COVID-19 and requiring supplemental oxygen. Outcomes included clinical improvement, defined as a two-point reduction in severity on a 6-point ordinal scale or discharge, and mortality within 28 days. We used Cox proportional-hazards models with propensity score inverse probability weighting to compare outcomes in patients who did and did not receive tocilizumab.ResultsWe evaluated 43 patients who received tocilizumab and 45 who did not. Patients receiving tocilizumab were younger with fewer comorbidities but higher baseline oxygen requirements. Tocilizumab treatment was associated with reduced CRP, fibrinogen, and temperature, but there were no meaningful differences in Cox models of time to clinical improvement (adjusted hazard ratio [aHR], 0.92; 95% CI, 0.38-2.22) or mortality (aHR, 0.57; 95% CI, 0.21-1.52). A numerically higher proportion of tocilizumab-treated patients had subsequent infections, transaminitis, and cytopenias.ConclusionsTocilizumab did not improve outcomes in hospitalized patients with COVID-19. However, this study was not powered to detect small differences, and there remains the possibility for a survival benefit. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|